CMTA Funds Cutting-Edge Gene-Editing Studies for Type 2 CMT
CMTA Funds Cutting-Edge Gene-Editing Studies for Type 2 CMT
CMTA—Gladstone Senior Investigator Bruce Conklin and Luke Judge from UC San Francisco recently received a grant from the Charcot-Marie-Tooth Association to develop the gene-editing technique known as CRISPR for application to CMT2A, 2E, and 2F.
Gladstone Experts Conklin Lab


